Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Neurocrine Biosciences, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
NBIX
Nasdaq
2836
www.neurocrine.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Neurocrine Biosciences, Inc.
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, a Long-Acting Corticotropin-Releasing Factor Type 1 Receptor Antagonist
- Jun 30th, 2025 2:05 pm
Neurocrine Biosciences Presents New Post-Hoc Data Analyses from KINECT®-HD Study Demonstrating Significant Reduction in Disease Burden with INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea
- Jun 27th, 2025 6:30 am
CPRX vs. NBIX: Which Stock Is the Better Value Option?
- Jun 23rd, 2025 9:40 am
Exploring 3 High Growth Tech Stocks In The US Market
- Jun 20th, 2025 11:38 am
Neurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia
- Jun 20th, 2025 6:30 am
Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer
- Jun 9th, 2025 2:05 pm
CPRX or NBIX: Which Is the Better Value Stock Right Now?
- Jun 3rd, 2025 9:40 am
Neurocrine Biosciences' Ingrezza to Meet Fiscal 2025 Sales Outlook, RBC Capital Says
- Jun 2nd, 2025 10:31 am
Neurocrine Biosciences Presents Patient-Reported Outcomes from KINECT-PRO™ Study Demonstrating INGREZZA® (valbenazine) Capsules Improved Functionality and Quality of Life in Patients with Tardive Dyskinesia
- Jun 2nd, 2025 6:30 am
Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors
- May 30th, 2025 2:30 pm
Neurocrine Biosciences, Inc. (NBIX)’s M4 Agonist Shows Promise in Schizophrenia Phase 2 Trial, Phase 3 Launched
- May 28th, 2025 10:03 pm
Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025
- May 28th, 2025 2:05 pm
Neurocrine Biosciences to Present Wide-Ranging One-Year Data from Phase 3 CAHtalyst™ Pediatric Study at Pediatric Endocrine Society 2025 Annual Meeting
- May 16th, 2025 6:30 am
Neurocrine Biosciences Presents Data Adding to the Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients with Tardive Dyskinesia
- May 16th, 2025 6:25 am
Neurocrine Biosciences Presents Data on Improvements in Physiologic Glucocorticoid Dosing and Select Reproductive Hormones in Patients with Classic Congenital Adrenal Hyperplasia Taking CRENESSITY™ (crinecerfont)
- May 15th, 2025 2:05 pm
GRFS or NBIX: Which Is the Better Value Stock Right Now?
- May 15th, 2025 9:40 am
Neurocrine Biosciences Presents Findings Contributing to the Growing Body of Evidence on the Impact of High-Dose Glucocorticoids on Clinical Outcomes in Congenital Adrenal Hyperplasia
- May 14th, 2025 2:05 pm
Neurocrine Biosciences, Inc. (NBIX): Among Billionaire Ken Griffin’s Midcap Stock Picks with Huge Upside Potential
- May 13th, 2025 1:48 pm
Investors Can Find Comfort In Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Quality
- May 12th, 2025 4:49 am
Neurocrine Biosciences, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
- May 8th, 2025 12:59 pm
Scroll